特兰胺酸用于血管素转化酶抑制剂诱导的血管:一项回顾性多中心研究
Kristen E Lindauer1, Bruce M Lo2, Gregory S Weingart2
1Pharmacy, Sentara Health, Virginia, United States.
The American journal of emergency medicine
|February 10, 2024
概括
特兰胺酸并没有改善患有血管激素转化酶抑制剂 (ACE-I) 血管的患者的结局. 这种治疗与更长的急诊室停留和增加ICU入院和输管治疗有关.
科学领域:
- 药理学 药理学是指药理学的学科.
- 紧急医疗 紧急医疗
- 关键的护理关键的护理
背景情况:
- ангиотензин转化酶抑制剂 (ACE-Is) 由于布拉迪基宁的积累,可以导致危及生命的血管.
- 作为一种抗纤维素解药物,特兰胺酸已被研究用于治疗ACE-I诱导的血管.
- 之前的病例报告表明,在ACE-I血管方面,酸具有潜在的益处.
研究的目的:
- 为了评估tranexamic acid在患有ACE-I诱导的血管的患者中的有效性和安全性.
- 为了比较治疗的患者与那些没有接受过tranexamic 酸治疗的患者之间的结果.
- 评估对急诊室停留时间,ICU入院和输管率的影响.
主要方法:
- 对患有ACE-I血管的患者提交ED的回顾性研究 (2018年1月至2021年8月).
- 患者接受特兰胺酸 (治疗组) 与未接受特兰胺酸 (对照组) 的患者的比较.
- 主要结果:急诊室停留时间 (LOS);次要结果:ICU入院,输管,安全事件.
主要成果:
- 与对照组 (n=189) 相比,治疗组 (n=73) 的ED LOS (20.9小时 vs 4.8小时) 显著长.
- 在tranexamic acid组中观察到更高的ICU入院率 (45%vs16%) 和输管率 (12%vs3%).
- 两组之间没有发现7天回归,血栓形成或死亡的显著差异.
结论:
- 在ACE-I血管中服用胺酸与ED LOS,ICU入院和输管增加有关.
- 观察到的不良事件的增加可能与患者表现的严重程度有关.
- 特兰胺酸对ACE-I血管似乎是安全的,但需要进一步的随机对照试验来确认有效性.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
640
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
640
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:25Antihypertensive Drugs: Direct Renin Inhibitors
629
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
629
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
731
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
731
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
514
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
514
01:16Antianginal Drugs: Nitrates and β-Blockers
590
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
590